| Category | Clinical Skincare |
| Founded | 2011 |
| Headquarters | Xi'an |
| Listing | Parent Giant Biogene listed on HKEX (02367.HK) |
| Latest revenue | Parent revenue RMB 5.52bn in 2025 |
| Hero SKUs | Recombinant Collagen Dressing / Collagen Ampoule |
Brand History
Comfy was launched in 2011 by Giant Biogene in Xi'an around recombinant collagen (originally called 'human-like collagen'). It started in hospitals and dermatology: medical-device dressings for post-procedure repair and sensitive skin built trust through doctors and clinical channels before extending into mainstream skincare. Giant Biogene listed on HKEX in November 2022, making Comfy the flagship of the recombinant-collagen story in public markets.
The real inflection came in 2021-22, when Comfy translated clinical 'dressing' language into a consumer 'single-dose ampoule' — the collagen stick became a phenomenon and lifted the brand from the RMB 1bn to the RMB 4bn tier. In 2025 group revenue was RMB 5.52bn, down 0.4%, with net profit of RMB 1.92bn, down 7.1% — the first simultaneous decline since listing. Comfy now sits in Sephora and China Duty Free, runs 44 experience stores, and has entered North America, Southeast Asia and East Asia.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 35.24 | +49.0% | 14.52 |
| 2024 | 55.39 | +57.2% | 20.62 |
| 2025 | 55.19 | -0.4% | 19.15 |
Brand-level：Comfy generated RMB 4.47bn in 2025, down 1.6% — its first decline since listing — while sister brand Collgene rose 9.2% to RMB 918m. Management attributes the drop to external shocks and intensifying price competition in clinical skincare.
Source：Giant Biogene 2025 annual report; company results announcements; trade press
Company Coverage
- 2026-04FY2025: first dual decline
Revenue RMB 5.52bn and net profit RMB 1.92bn, which management links to external shocks and price competition at Comfy.
Source：Giant Biogene FY2025 report - 2025-10Class III collagen device approved
A recombinant type I collagen lyophilised fibre won NMPA approval, deepening the medical moat.
Source：NMPA announcement - 2025-08Going global
44 experience stores plus Sephora, CDF and entries into North America and Southeast Asia.
Source：Company report
Editor's note: Comfy's success was converting device-grade credibility into cosmetic repurchase. It proved Chinese clinical skincare can earn a premium from upstream technology — and exposed the ceiling of that playbook: once recombinant collagen becomes table stakes, a RMB 4.4bn brand must answer what it sells besides an ingredient.